Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory Diseases.
Journal: Journal of medicinal chemistry
Published: October 30, 2025
Impact of missing patient report outcomes in clinical trials for ulcerative colitis: Should we always assume treatment failure?
Journal: Crohn's & colitis 360
Published: June 17, 2025
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: July 11, 2024
Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects.
Journal: Science translational medicine
Published: December 20, 2023
A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers.
Journal: Clinical and translational science
Published: June 16, 2023
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc).
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: June 16, 2023
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.
Journal: Annals of clinical and translational neurology
Published: December 09, 2021
Upregulation of BMI1-suppressor miRNAs (miR-200c, miR-203) during terminal differentiation of colon epithelial cells.
Journal: Journal of gastroenterology
Published: May 13, 2021
Rates of Major Cardiovascular Events in Severe Asthma: U.S. Real-World and Clinical Trial-Eligible Populations.
Journal: Annals of the American Thoracic Society
Published: February 19, 2021
Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers.
Journal: Clinical drug investigation
Published: July 25, 2019
Last Updated: 09/26/2026